Wells Fargo raises Ascendis Pharma stock price target on growth outlook

Wells Fargo raised its price target for Ascendis Pharma (ASND) to $330 from $326, citing strong growth prospects and underappreciated operating leverage. The company reported Q3 earnings and revenue exceeding estimates, driven by its rare-disease portfolio. Management expects continued growth in Yorvipath, with international expansion supporting a €5 billion 2030 revenue target.

Original reporting
Published Nov 13, 2026, 10:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASND
Bullish
high confidence
Mentioned
$ASND
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ASNDBullishMed
01

Why it matters

The earnings beat and higher target may attract new buying, especially from investors focused on high‑margin biotech firms.

02

Market read

Positive earnings and analyst upgrade provide a short‑term catalyst for ASND.

03

What to watch

Potential regulatory or reimbursement risks for rare‑disease therapies.

Relevance 7/10Novelty 8/10Timing: after‑hours

Background

Ascendis Pharma reported Q3 earnings that beat expectations and raised its revenue outlook, prompting Wells Fargo to lift its price target.

Company-level read

Ticker impact

$ASNDBullishHigh confidence
Context

Wells Fargo raised its price target on Ascendis Pharma to $330 and reported better‑than‑expected Q3 earnings and revenue.

Expected impact

potential upside as the market prices in higher earnings expectations

Evidence & confidence

The price‑target increase and earnings beat are fresh facts that can drive buying interest.

Market effects

Strong earnings may lift other rare‑disease biotech peers.

U.S. biotech sector could see modest gains.

Limited to biotech investors; no broad market effect.

Counterpoint

If the growth outlook proves overly optimistic, the stock could face a pull‑back.

Key entities

  • Ascendis Pharma

    Biopharma focused on rare‑disease treatments.

  • Wells Fargo

    Raised price target to $330.

Related articles

$ASNDMed

TD Cowen raises Ascendis Pharma stock price target on revenue beat

TD Cowen raised its price target for Ascendis Pharma (ASND) to $352, citing strong Q3 revenue beats across its products. Revenue grew 86% YoY with a 92% gross margin. The company reaffirmed long-term revenue targets of €5B by 2030 and €10B by 2035. ASND stock trades near its 52-week high at $266.31. Other analysts also raised targets and maintained positive ratings.

$ASNDMedAI 8/10

Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH

Ascendis Pharma AS reported Q3 2026 revenue up 89%, driven by YORVIPATH. CEO Jan Mikkelsen discussed new therapeutic areas, ex-US growth, and YUVIWEL's potential. The company expects steady US uptake and EUR5B 2030 sales. CFO Scott Smith noted EUR330M spent on share buybacks, with EUR600M operating cash flow guided for 2026. Margins improved to mid-40s, with no major commercial infrastructure changes expected.

$ASNDHighAI 8/10

Ascendis Pharma earnings analysis: questions answered and next catalysts

Ascendis Pharma (ASND) reported Q3 2026 earnings, beating revenue and EPS estimates. Shares rose 2.93% to $266.88. Key drugs showed strong demand, and the company increased its cash flow outlook. Management addressed growth, funding, and competition. Next catalysts include regulatory decisions, clinical trials, and market expansion. Analysts debate valuation and future growth prospects.

$ASNDHighAI 8/10

Ascendis (ASND) Q3 2026 Earnings Call Transcript

Ascendis (ASND) reported Q3 2026 product revenue of €366 million, up 89% YoY. Key drivers: growth in existing products (Yorvipath, Yuvivel, Skytrofa), indication expansions, and new products. Yorvipath revenue was €291 million, up 103% YoY. Yuvivel and Skytrofa also showed strong demand. The company aims for €5 billion in annual revenue by 2030.

HighAI 8/10

Why is Ascendis Pharma stock climbing today?

Ascendis Pharma's stock rose 0.5% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of €1.08 vs. €0.80 and revenue of €369.7M vs. €363.0M. YORVIPATH sales grew 103% YoY to €291M. The company also repurchased 2M shares for $459M and received positive EU regulatory opinions for TransCon CNP.